ABT-333
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relative Bioavailability
Conditions
Relative Bioavailability
Trial Timeline
Nov 1, 2013 → Dec 1, 2013
NCT ID
NCT02052349About ABT-333
ABT-333 is a phase 1 stage product being developed by AbbVie for Relative Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT02052349. Target conditions include Relative Bioavailability.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02052349 | Phase 1 | Completed |
| NCT00726882 | Phase 2 | Completed |
Competing Products
6 competing products in Relative Bioavailability
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab + Sonelokimab | MoonLake Immunotherapeutics | Phase 1 | 28 |
| BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg | AstraZeneca | Phase 1 | 33 |
| D1400147 + D14000136 + D14000137 + Epanova® | AstraZeneca | Phase 1 | 33 |
| Ropivacaine 0.1% + Ropivacaine 0.4% | Baxter | Approved | 82 |
| Sulfatinib T capsule + Sulfatinib R capsule | HUTCHMED | Phase 1 | 28 |
| Tebipenem tablet form | Spero Therapeutics | Phase 1 | 25 |